You searched for "simulator"
The incidence of retinal vein occlusion in patients with pseudoexfoliation glaucoma
In this retrospective study the authors aimed to evaluate PXF as an independent risk factor for the occurrence of retinal vein occlusion (RVO). Three hundred PXF glaucoma patients (PXF group), 300 non-PXF glaucoma patients, and 599 non glaucoma non-PXF (nGnP...Looking on the brightside: Lord David Blunkett
“I can hear people smile” As a young adult in the 1980s and 1990s I gradually became more politically informed with occasional forays into BBC’s Question Time. In doing so, I learnt of the rise of politician David Blunkett, a...The Case of Dr Bawa-Garba – Do we truly have a ‘no blame’ culture?
Eye News’ medico-legal specialist shares his thoughts on the recent acquittal of Dr Bawa-Garba. On 13 August 2018 the Court of Appeal ruled that Dr Hadiza Bawa-Garba should be reinstated on the UK medical register. The Court of Appeal rejected...Myasthenia gravis presenting with isolated ptosis: a poorly studied subgroup
Investigation into the cause of one isolated symptom or sign can be challenging if that particular sign may be caused by a variety of pathological processes, affecting different tissues, and presenting to different specialties. Unilateral ptosis is a case in...Protecting and recovering from email hacking
Over the last 12 months I have received emails from more than 20 friends and acquaintances (mostly doctors) who didn’t send those emails. More often than not I find the emails in my ‘Spam’ folder as Gmail knows they are...Ciliatech presents preliminary results on treating glaucoma with CID at Ophthalmology Futures Symposium
Ciliatech presents preliminary one-year study results on treating open- and narrow-angle glaucoma with CID at Ophthalmology Futures Symposium.Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...
Outcomes of primary and repeat DSAEKs
Retrospective analysis of results following primary and secondary descemet stripping automated endothelial keratoplasty (DSAEKs), carried out in Villa Serena-Villa Igea Private Hospitals in Italy, showed that primary and secondary DSAEK surgery result in similar visual outcomes, refractive errors and endothelial...
Systemic anti-inflammatory versus fluocinolone acetonide intraocular implant
In the Multicenter Uveitis Steroid Treatment (MUST) trial, 255 patients with intermediate uveitis, posterior uveitis or panuveitis were randomised to either fluocinolone acetonide intraocular implant or systemic corticosteroid therapy which was supplemented with immunosuppression if required. Patients were followed up...
Long-term retinal changes following unilateral retrobulbar optic neuritis
The aim of this study was to assess the longitudinal changes in retinal nerve fibre layer (RNFL) thickness after a first attack of optic neuritis and to investigate the impact of treatment on RNFL thinning at one year after the...
Ranibizumab for the treatment of age-related macular degeneration
This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...
